The result is improved fasting and postprandial glucose levels
MedShadow.org is dedicated to empowering people with our evidence-based journalism about the safest ways to take over-the-counter (OTC) and prescription (Rx) medications
Retatrutide for the treatment of obesity, obstructive sleep apnea and related conditions TRIUMPH clinical development programme
For type 2 diabetes management , NICE guideline NG28 recommends considering GLP-1 receptor agonists when: Triple therapy with metformin and two other oral medications is ineffective, not tolerated or contraindicated The patient has a body mass index (BMI) of 35 kg/m or higher (with lower thresholds for people from certain ethnic backgrounds), or lower BMI with specific clinical circumstances where weight loss would benefit other obesity-related comorbidities Insulin would have significant occupational implications GLP-1 therapy should only be continued beyond six months if there has been a beneficial metabolic response, defined as a reduction in HbA1c of at least 11 mmol/mol (1.0 percentage point) and weight loss of at least 3% of initial body weight
There is no single national answer: Access depends on state decisions, specific program rules and whether a formulation is approved for diabetes versus an obesity indication
doi: 10.1152/ajpgi.00361.2020 164
